Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark E Cooper

Showing results (321-330 of 399) with videos related to

Pageof 40
Sort By:
Aging|March 9, 2021
Early-onset of type 2 diabetes mellitus is a risk factor for diabetic nephropathy progression: a biopsy-based studyYucheng Wu, Yiting Wang, Junlin Zhang, et al.
Renal Failure|April 4, 2022
Development and internal validation of machine learning algorithms for end-stage renal disease risk prediction model of people with type 2 diabetes mellitus and diabetic kidney diseaseYutong Zou, Lijun Zhao, Junlin Zhang, et al.
Pathogens (Basel, Switzerland)|August 26, 2022
Elevated Fasting Blood Glucose Levels Are Associated with Worse Clinical Outcomes in COVID-19 Patients Than in Pneumonia Patients with Bacterial InfectionsWenjun Wang, Zhonglin Chai, Mark E Cooper, et al.
American Journal of Nephrology|January 17, 2015
Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathyLuis M Ruilope, Rajiv Agarwal, Juliana C Chan, et al.
JAMA Cardiology|January 3, 2024
Hypoglycemia and Cardiovascular Outcomes in the CARMELINA and CAROLINA Trials of Linagliptin: A Secondary Analysis of Randomized Clinical TrialsNikolaus Marx, Ahmed A Kolkailah, Julio Rosenstock, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|March 14, 2023
Pyridoxamine prevents increased atherosclerosis by intermittent methylglyoxal spikes in the aortic arches of ApoE<sup>-/-</sup> miceNordin M J Hanssen, Chris Tikellis, Raelene J Pickering, et al.
Diabetes|April 4, 2025
miR-214 and its primary transcript Dnm3os regulate fibrosis and inflammation through RAGE signalling in diabetic kidney diseaseShinji Hagiwara, Jun Okabe, Mark Ziemann, et al.
Frontiers in Endocrinology|December 27, 2021
High Fasting Blood Glucose Level With Unknown Prior History of Diabetes Is Associated With High Risk of Severe Adverse COVID-19 OutcomeWenjun Wang, Zhonglin Chai, Mark E Cooper, et al.
Clinical Chemistry and Laboratory Medicine|March 26, 2013
Plasma advanced glycation end products (AGEs) and NF-κB activity are independent determinants of diastolic and pulse pressureKarly C Sourris, Jasmine G Lyons, Sonia L Dougherty, et al.
Diabetes, Obesity & Metabolism|June 22, 2017
Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA-T2D trialPer-Henrik Groop, Mark E Cooper, Vlado Perkovic, et al.
Pageof 40

Showing results (321-330 of 399) with videos related to

Sort By:
Pageof 40
Aging|March 9, 2021
Early-onset of type 2 diabetes mellitus is a risk factor for diabetic nephropathy progression: a biopsy-based studyYucheng Wu, Yiting Wang, Junlin Zhang, et al.
Renal Failure|April 4, 2022
Development and internal validation of machine learning algorithms for end-stage renal disease risk prediction model of people with type 2 diabetes mellitus and diabetic kidney diseaseYutong Zou, Lijun Zhao, Junlin Zhang, et al.
Pathogens (Basel, Switzerland)|August 26, 2022
Elevated Fasting Blood Glucose Levels Are Associated with Worse Clinical Outcomes in COVID-19 Patients Than in Pneumonia Patients with Bacterial InfectionsWenjun Wang, Zhonglin Chai, Mark E Cooper, et al.
American Journal of Nephrology|January 17, 2015
Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathyLuis M Ruilope, Rajiv Agarwal, Juliana C Chan, et al.
JAMA Cardiology|January 3, 2024
Hypoglycemia and Cardiovascular Outcomes in the CARMELINA and CAROLINA Trials of Linagliptin: A Secondary Analysis of Randomized Clinical TrialsNikolaus Marx, Ahmed A Kolkailah, Julio Rosenstock, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|March 14, 2023
Pyridoxamine prevents increased atherosclerosis by intermittent methylglyoxal spikes in the aortic arches of ApoE<sup>-/-</sup> miceNordin M J Hanssen, Chris Tikellis, Raelene J Pickering, et al.
Diabetes|April 4, 2025
miR-214 and its primary transcript Dnm3os regulate fibrosis and inflammation through RAGE signalling in diabetic kidney diseaseShinji Hagiwara, Jun Okabe, Mark Ziemann, et al.
Frontiers in Endocrinology|December 27, 2021
High Fasting Blood Glucose Level With Unknown Prior History of Diabetes Is Associated With High Risk of Severe Adverse COVID-19 OutcomeWenjun Wang, Zhonglin Chai, Mark E Cooper, et al.
Clinical Chemistry and Laboratory Medicine|March 26, 2013
Plasma advanced glycation end products (AGEs) and NF-κB activity are independent determinants of diastolic and pulse pressureKarly C Sourris, Jasmine G Lyons, Sonia L Dougherty, et al.
Diabetes, Obesity & Metabolism|June 22, 2017
Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA-T2D trialPer-Henrik Groop, Mark E Cooper, Vlado Perkovic, et al.
Pageof 40